98 related articles for article (PubMed ID: 23528280)
1. Development of cyclosporine A-loaded dry-emulsion formulation using highly purified glycerol monooleate for safe inhalation therapy.
Sato H; Ogawa K; Kojo Y; Kawabata Y; Mizumoto T; Yamada S; Onoue S
Int J Pharm; 2013 May; 448(1):282-9. PubMed ID: 23528280
[TBL] [Abstract][Full Text] [Related]
2. Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.
Onoue S; Sato H; Ogawa K; Kojo Y; Aoki Y; Kawabata Y; Wada K; Mizumoto T; Yamada S
Eur J Pharm Biopharm; 2012 Jan; 80(1):54-60. PubMed ID: 22008148
[TBL] [Abstract][Full Text] [Related]
3. [Strategic formulation study on dry powder inhalation system based on modulated molecular properties and controlled pharmacokinetics].
Onoue S
Yakugaku Zasshi; 2013; 133(1):93-8. PubMed ID: 23292025
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical stability study on cyclosporine A loaded dry-emulsion formulation with enhanced solubility.
Sato H; Ogawa K; Kojo Y; Suzuki H; Mizumoto T; Onoue S
Chem Pharm Bull (Tokyo); 2015; 63(1):54-8. PubMed ID: 25743195
[TBL] [Abstract][Full Text] [Related]
5. Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats.
Onoue S; Aoki Y; Matsui T; Kojo Y; Misaka S; Mizumoto T; Yamada S
Int J Pharm; 2011 May; 410(1-2):54-60. PubMed ID: 21419198
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy.
Onoue S; Sato H; Kawabata Y; Mizumoto T; Hashimoto N; Yamada S
J Control Release; 2009 Aug; 138(1):16-23. PubMed ID: 19376169
[TBL] [Abstract][Full Text] [Related]
7. Self-micellizing solid dispersion of cyclosporine A for pulmonary delivery: Physicochemical, pharmacokinetic and safety assessments.
Suzuki H; Ueno K; Mizumoto T; Seto Y; Sato H; Onoue S
Eur J Pharm Sci; 2017 Jan; 96():107-114. PubMed ID: 27634579
[TBL] [Abstract][Full Text] [Related]
8. Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats.
Misaka S; Aoki Y; Karaki S; Kuwahara A; Mizumoto T; Onoue S; Yamada S
Peptides; 2010 Jan; 31(1):72-8. PubMed ID: 19808073
[TBL] [Abstract][Full Text] [Related]
9. Development of inhalable nanocrystalline solid dispersion of tranilast for airway inflammatory diseases.
Onoue S; Aoki Y; Kawabata Y; Matsui T; Yamamoto K; Sato H; Yamauchi Y; Yamada S
J Pharm Sci; 2011 Feb; 100(2):622-33. PubMed ID: 20653048
[TBL] [Abstract][Full Text] [Related]
10. Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.
Kawabata Y; Aoki Y; Matsui T; Yamamoto K; Sato H; Onoue S; Yamada S
Eur J Pharm Biopharm; 2011 Jan; 77(1):178-81. PubMed ID: 21081161
[TBL] [Abstract][Full Text] [Related]
11. Chemical synthesis and formulation design of a PEGylated vasoactive intestinal peptide derivative with improved metabolic stability.
Onoue S; Matsui T; Kato M; Mizumoto T; Liu B; Liu L; Karaki S; Kuwahara A; Yamada S
Eur J Pharm Sci; 2013 Jun; 49(3):382-9. PubMed ID: 23608612
[TBL] [Abstract][Full Text] [Related]
12. Novel dry powder formulation of ovalbumin for development of COPD-like animal model: Physicochemical characterization and biomarker profiling in rats.
Misaka S; Sato H; Yamauchi Y; Onoue S; Yamada S
Eur J Pharm Sci; 2009 Jun; 37(3-4):469-76. PubMed ID: 19491038
[TBL] [Abstract][Full Text] [Related]
13. Self-micellizing solid dispersion of cyclosporine A with improved dissolution and oral bioavailability.
Onoue S; Suzuki H; Kojo Y; Matsunaga S; Sato H; Mizumoto T; Yuminoki K; Hashimoto N; Yamada S
Eur J Pharm Sci; 2014 Oct; 62():16-22. PubMed ID: 24836392
[TBL] [Abstract][Full Text] [Related]
14. Inhalable sustained-release formulation of long-acting vasoactive intestinal peptide derivative alleviates acute airway inflammation.
Onoue S; Matsui T; Kuriyama K; Ogawa K; Kojo Y; Mizumoto T; Karaki S; Kuwahara A; Yamada S
Peptides; 2012 Jun; 35(2):182-9. PubMed ID: 22484228
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporin nanosphere formulation for ophthalmic administration.
Khan W; Aldouby YH; Avramoff A; Domb AJ
Int J Pharm; 2012 Nov; 437(1-2):275-6. PubMed ID: 22951866
[TBL] [Abstract][Full Text] [Related]
16. Spray dried glyceryl monooleate-magnesium trisilicate dry powder as cubic phase precursor.
Shah MH; Biradar SV; Paradkar AR
Int J Pharm; 2006 Oct; 323(1-2):18-26. PubMed ID: 16846704
[TBL] [Abstract][Full Text] [Related]
17. Self-assembled micellar formulation of chafuroside A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.
Onoue S; Matsui T; Aoki Y; Ishida H; Nukaya H; Kou K; Yamada S
Eur J Pharm Sci; 2012 Jan; 45(1-2):184-9. PubMed ID: 22108345
[TBL] [Abstract][Full Text] [Related]
18. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation.
Nguyen TH; Hanley T; Porter CJ; Larson I; Boyd BJ
J Pharm Pharmacol; 2010 Jul; 62(7):856-65. PubMed ID: 20636873
[TBL] [Abstract][Full Text] [Related]
19. Application of a Novel Instantized Glycerol Monooleate Ingredient in a Protein-Stabilized Oil-In-Water Emulsion.
Loi CC; Eyres GT; Silcock P; Birch EJ
Foods; 2020 Sep; 9(9):. PubMed ID: 32899737
[TBL] [Abstract][Full Text] [Related]
20. Biopharmaceutical Evaluation of Novel Cyclosporine A Nano-matrix Particles for Inhalation.
Sato H; Suzuki H; Yakushiji K; Wong J; Seto Y; Prud'homme RK; Chan HK; Onoue S
Pharm Res; 2016 Sep; 33(9):2107-16. PubMed ID: 27225495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
